Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Friday reported upbeat fourth-quarter earnings.
The company posted adjusted earnings of $11.44 per share, down 5% year-over-year, beating the consensus of $10.71. The company reported sales of $3.88 billion, up 3% year over year, beating the consensus of $3.79 billion.
Regeneron expects fiscal 2026 GAAP gross margin of 79%–80%, with adjusted gross margin of 83%–84%. The company forecasts adjusted R&D expenses of $5.9–$6.1 billion in 2026, and non-GAAP SG&A expenditure between $2.5 billion and $2.65 billion.
“Regeneron performed well in 2025, with financial strength driven by our four blockbuster medicines and future growth supported by our exciting late-stage clinical portfolio,” said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron.
Regeneron Pharmaceuticals shares gained 2.1% to trade at $756.63 on Monday.
These analysts made changes to their price targets on Regeneron Pharmaceuticals following earnings announcement.
- Truist Securities analyst Gregory Renza maintained Regeneron Pharmaceuticals with a Buy and lowered the price target from $820 to $818.
- Cantor Fitzgerald analyst Carter Gould maintained the stock with an Overweight rating and raised the price target from $740 to $800.
- Wells Fargo analyst Mohit Bansal maintained Regeneron Pharmaceuticals with an Equal-Weight rating and raised the price target from $745 to $800.
- Morgan Stanley analyst Matthew Harrison maintained the stock with an Equal-Weight rating and raised the price target from $768 to $769.
Considering buying REGN stock? Here’s what analysts think:
Photo via Shutterstock